Catalyst
Slingshot members are tracking this event:
Incyte (INCY) phase 3 interim readout for Keytruda and epacadostat combo in advanced melanoma is expected in Q1, 2018. - Discontinued
- Source Link:
- https://clinicaltrials.gov/ct2/show/NCT02752074
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| INCY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 06, 2018
Occurred Source:
http://www.incyte.com/ir/press-releases.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ido1, Discontinued
